anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study aims to investigate the effects of Gualou Xiebai Banxia Decoction(GXBD) on type 2 diabetes mellitus(T2DM) combined with acute myocardial infarction(AMI) in rats via chemerin/chemokine-like receptor 1(CMKLR1)/peroxisome proliferator-activated receptor α(PPARα) signaling pathway, and to explore the mechanism of GXBD in alleviating glucose and lipid metabolism disorders. The SD rats were randomized into control, model, positive control, and low-and high-dose GXBD groups. The rat model of T2DM was established by administration with high-fat emulsion(HFE) by gavage and intraperitoneal injection with streptozotocin, and then coronary artery ligation was performed to induce AMI. The control and model groups were administrated with the equal volume of normal saline, and other groups were administrated with corresponding drugs by gavage. Changes in relevant metabolic indicators were assessed by ELISA and biochemical assays, and the protein levels of chemerin, CMKLR1, and PPARα in the liver, abdominal fat, and heart were determined by Western blot. The results showed that GXBD alleviated the myocardial damage and reduced the levels of blood lipids, myocardial enzymes, and inflammatory cytokines, while it did not lead to significant changes in blood glucose. Compared with the model group, GXBD down-regulated the expression of chemerin in peripheral blood and up-regulated the expression of cyclic adenosine monophosphate(cAMP) and protein kinase A(PKA) in the liver. After treatment with GXBD, the protein levels of chemerin and CMKLR1 in the liver, abdominal fat, and heart were down-regulated, while the protein levels of PPARα in the liver and abdominal fat were up-regulated. In conclusion, GXBD significantly ameliorated the disorders of glycolipid metabolism in the T2DM-AMI model by regulating the chemerin/CMKLR1/PPARα signaling pathway to exert a protective effect on the damaged myocardium. This study provides a theoretical basis for further clinical study of GXBD against T2DM-AMI and is a manifestation of TCM treatment of phlegm and turbidity causing obstruction at the protein level.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to a pharmaceutical composition for treating iron overload in powder form containing 25 wt. % to 45 wt. % of combination of lactose and sucrose with respect to total weight of powder and containing as an active ingredient from 35 wt. % to 40 wt. % of the compound represented by formula 1, or its pharmaceutically acceptable salt and from 0.2 wt. % to 10 wt. % of sodium lauryl sulphate with respect to total weight of powder. Invention also relates to a method for preparing a pharmaceutical composition in powder form.[Formula 1].EFFECT: technical result: obtaining a pharmaceutical composition in powder form, containing deferasirox as an active ingredient and low percentage content of additives, which can be taken without suspension in the aqueous phase, in addition, the obtained pharmaceutical composition exhibits high rate of dissolution.12 cl, 7 dwg, 10 tbl, 7 ex
Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, start dosing at the low end of the dosing range, and monitor patients for adverse effects [see Warnings and Precautions (5.1, 5.2, 5.3, 5.6, 5.13)]. 

Of the total number of subjects treated with VOLTAREN® GEL in clinical studies, 498 were 65 years of age and over. No overall differences in effectiveness or safety were observed between these subjects and younger subjects, but greater sensitivity to the effect of NSAIDs in some older individuals cannot be ruled out.

Diclofenac, as with any NSAID, is known to be substantially excreted by the kidney, and the risk of toxic reactions to VOLTAREN® GEL may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken when using VOLTAREN® GEL in the elderly, and it may be useful to monitor renal function.
Participants randomized to receive the inotrope will be initiated on inotrope therapy at starting doses and titrated according to standard clinical care. During reassessment, the treating physicians will make a decision about adjustment of the inotrope dose (increase, maintain or decrease) based on hemodynamics, end-organ perfusion, vasopressor support and clinical exam. Dobutamine doses will be 2.5, 5.0, 7.5, 10 and \>10 ug/kg/min and milrinone doses will be 0.125, 0.250, 0.375, 0.5 and \>0.5 ug/kg/min. These dose stages are identical to those used in Capital Do-Re-Mi and reflect current standard of care.
The present invention discloses a mould catching agent capable of effectively catching mycotoxin entering the human body along with foods, which is a powder containing the nanometer pore diameter and is prepared from that smectite is calcined for 2 to 4 hr at the temperature of 150 DEG C to 400 DEG C, and then the pressure is reduced and the temperature is reduced to normal temperature, and finally the calcined smectite is crushed and screened. The mould catching agent has the final physical properties: the moisture is lower than 9%, the density is 0.8 g/milliliter, and the particle size is from 50% to 75%. The mould catching agent is screened by 325 meshes of sieves. The mould catching agent can actively catch the mycotoxin entering the human body along with the foods, and the toxin is discharged from the human body through intestinal canals. Thereby, the mycotoxin in the liver, the blood and the intestinal canal of the human is efficiently removed, and finally, the purpose of protecting the human body health is realized. The present invention can be used as a liver protecting medicine and a mould-driving health-care products and a main component of a toxinicide for mycotoxin in the liver, the blood and the intestinal canals of the human.
Provided are an attenuation method for influenza viruses, an attenuated influenza virus strain, and the use. The attenuation method comprises: deleting bases of an arbitrary number at random positions on an influenza virus conserved region M2 protein transmembrane domain and a cytoplasmic domain to obtain attenuated influenza viruses having corresponding base deletion. The attenuated influenza virus strain obtained by means of the attenuation method has good growth characteristics on an MDCK cell line expressing M2 protein. The virus strain of a high dose can grow in MDCK cells or chicken embryos and has high chicken erythrocyte agglutination titer. Balb/C mouse immunization by means of nasal instillation shows that: compared with parental virus IAV PR8, said strain is non-pathogenic to the mice. The random base deletion mode reduces the virulence of the influenza viruses, and lays a foundation for screening of a safer and more effective live attenuated IAV vaccine.
The invention relates to a plaster used for treating hepatitis B. The plaster is a current external product specially used for treating hepatitis B. Hepatitis B is caused by hepatitis B virus, and is a communicable disease with main results of hepatic lesions and hepatic necrosis lesions. The disease has high communicability, wide epidemic area and high incidence rate. The disease is a horrible disease which is hard to cure. The plaster is prepared from 11 Chinese herbal medicines such as cape jasmine, capillary wormwood herb, and rhubarb. The plaster provides hepatoprotection effects. Therefore, the plaster provides substantial treatment effects for liver disease patients.
PURPOSE: To obtain a cell-dissolving substance GMD 1630 capable of applying to the treatment of cancer by extracting the resin of Garcinia morella Desv., and treating the extract with sedimentation. CONSTITUTION: The resin of Garcinia morella Desv.(GMD) is finely crushed, the powder is dipped in anhydrous alcohol, the extraction solution is incubated at ambient temperature until it becomes saturated, subsequently the resultant alcohol extract is diluted with water to 3-10 times volume, and the liquid is subjected to centrifugal separation to obtain sediments. The above treatment are repeated to obtain a purified GMD 1630. Alternatively, the GMD resin is dissolved in distilled water, the solution is extracted with chloroform/water (1:1). The extraction is repeated until the most part of yellow component is aqueous layer is transferred into the chloroform layer. The lower layers are collected and chloroform is evaporated to condense GMD 1630.  GMD 1630 is identified by the absorption bands of 1630, 1540, 1590, 1430 and 1140cm<-1> is infrared spectrum, and further as a shortcut method, the substance is identified by the feature that, when an absorption zone of 290-360nm in a visual and ultraviolet spectrum is measured, the absorption is lowest at 315nm and ratios of peaks 290:315:306(nm)=2:1:2.
Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
A renal function failure disease is a common disease and a frequently encountered disease, and especially, persons in middle and old age are easy to have renal function failure diseases. But sometimes, people do not pay much attention to renal function failure diseases, and when renal function failure diseases become serious, people go to hospitals to be examined. People ask doctors to diagnose and prescribe, and purchase medicine, such as 'renal aid ', sold on markets. Because the price of the medicine is dear, and after taking about three parts of the medicine or purchasing about three bottles of the medicine, people stop to take the medicine because of expenses deficiency. Therefore, the optimum cure period of renal function failure diseases is delayed, and aftereffects are bad. The present invention discloses Shouwu tea prepared by taking a plant Chinese medicinal herb, namely 'fleeceflower root ' as a main raw material to the society, and six products, such as a fleeceflower root tea tablet, a Shouwu tea tablet, a fleeceflower root vine tea tablet, a powdery fleeceflower root tea bag, a powdery Shouwu tea bag and a Shouwu tea liquid drink, are prepared. Through the clinical application to 38 cases, the effective rate is 100%, and the cure rate is 79%. The Shouwu tea integrates renal function failure prevention and cure into tea drinking, has low price, is convenient to drink, and a has good effect. The purposes of early prevention, early cure and body building are achieved, and the Shouwu tea can reduce blood fat and osteoporosis, and prevent the occurrence of high blood pressure, apoplexy and coronary diseases.
While the relationship between single receptor lymphocytes and cancer has been deeply researched, the origin and biological roles of dual receptor lymphocytes in tumor microenvironment (TME) remain largely unknown. And since nasopharyngeal carcinoma (NPC) is a type of cancer closely associated with immune infiltration, studying the TME of NPC holds particular significance. Utilizing single-cell RNA sequencing combined with T cell receptor (TCR) and B cell receptor (BCR) sequencing (scRNA + TCR + BCR-seq), we analyzed data from 7 patients with NPC and 3 patients with nasopharyngeal lymphatic hyperplasia (NLH). In our research, it was firstly found that the presence of dual receptor lymphocytes in both the TME of NPC and the inflammatory environment of NLH. We also confirmed their clonal expansion, suggesting their potential involvement in the immune response. Subsequently, we further discovered the lineage and the pairing characteristics. It was found that the dual receptor lymphocytes in NPC and NLH mainly originate from memory cells, and the predominant pairing type for dual TCR was β+α1+α2 and dual BCR was heavy+κ+λ. By further analyzing their gene expression, we compared the function of dual receptor cells with single receptor cells in the context of both NPC and NLH. This groundbreaking research has enhanced our comprehension of the features of dual-receptor cells and has contributed to a better understanding of the TME in NPC. By comparing with NLH, it illuminates part of the alterations in the process of malignant transformation in NPC. These findings present the potential to acquire improved diagnostic markers and treatment modalities.
The attention control condition will incorporate face-valid content to support college readiness and achievement in twelve 60- minute group sessions. Twelve sessions will cover the SOAR study skills curriculum (Kruger, 2017), including goal-setting, organization and time-management, and study skills for reading comprehension, writing papers, note-taking, and test-taking.
The invention relates to a preparation method of a traditional Chinese medicine for treating infantile adiposis, belonging to the technical field of preparation methods of traditional Chinese medicines. The existing method for treating infantile adiposis generally adopts various medicines in Western medicine, has the defects of high price and poor effect, and can easily cause some untoward reactions. The technical scheme is as follows: the method comprises the following steps: taking equal parts of rhizoma atractylodis, dried orange peel, tuber pinellia, tuckahoe, rhizoma alismatis, lotus leaf, charred hawthorn, honey-fried licorice root, oriental wormwood and raw rhubarb, immersing the drugs in 800ml of water for 35 minutes, and decocting with soft fire for 30 minutes to obtain 200ml of decoction, wherein the decoction is the traditional Chinese medicine for treating infantile adiposis. The traditional Chinese medicine is decocted and taken in the morning, which is based on the theory of Seeking Yin in Yang. The traditional Chinese medicine for treating infantile adiposis has the advantages of simple preparation process and low price. The prepared traditional Chinese medicine decoction has the advantages of small toxic and side effects, short treatment course and high cure rate. While using the Chinese drugs, the traditional Chinese medicine avoids untoward reactions, anaphylactic reactions and toxic reactions caused by Western medicine.
Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.
Focus groups and/or individual interviews will be conducted in-person and/or remotely to receive feedback on the HPV vaccine education materials. Focus groups and/or individual interviews will be conducted with 24 young adult Latino men who have sex with men (YLMSM) in either English or Spanish (approximately 12 in Puerto Rico and approximately 12 in Florida). The purpose will be to gain feedback on the acceptability, accessibility, content, delivery preference, and aesthetics of the theoretically informed HPV education materials culturally targeted for Spanish- and/or English-speaking YLMSM.
The trial will be divided into 2 parts: Phase I and Phase II.

The Phase I study will adopt a Bayesian Continual Reassessment Method. Patients will receive single-agent abiraterone run-in of 500 mg orally, once daily (continuous dosing) along with prednisolone at 5 mg BD until PSA progression on abiraterone monotherapy is confirmed. This run-in will not be required if patients have been treated with abiraterone in the previous 6 months. Upon confirmation of PSA progression, tildrakizumab IV will be started and given once every 4-weeks in combination with the fixed dose abiraterone (and prednisolone). The starting dose of tildrakizumab will be 100mg, with single dose escalations to 300mg and 600mg to determine the RP2D to take forward to the Phase II study. Depending on the number of responses observed, dose levels that are deemed tolerable may be expanded to up to a total of 10 patients who are evaluable for response.

The Phase II study will employ a two-stage Minimax design, recruiting up to 25 patients. During the first stage, 15 evaluable patients will be enrolled and followed for a minimum of 2 cycles each. If there are one or more responses confirmed at least 4-weeks later, an additional 10 evaluable patients will be recruited. If 4 or more responses are seen in the 25 patients evaluable for response, the combination will be deemed successful, warranting further evaluation in subsequent phases of testing. In the phase II study, patients will start taking 500mg abiraterone as an oral tablet once daily along with 5mg of prednisolone twice daily until PSA progression on abiraterone monotherapy is confirmed. This run-in will not be required if patients have been treated with abiraterone in the previous 6 months. Upon confirmation of PSA progression, the tildrakizumab will be given as an intravenous infusion at the dose established in the Phase I safety part of the study in combination with the abiraterone (and prednisolone) from combination Cycle 1 Day 1 onwards.
Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure; MULTAQ doubles the risk of death. (14.3) MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure. (4, 5.1)

In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure. (14.4). MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm. (4, 5.2)
Anoxia in the mammalian brain leads to hyper-excitability and cell death; however, this cascade of events does not occur in the anoxia-tolerant brain of the western painted turtle, Chrysemys picta belli. The painted turtle has become an important anoxia-tolerant model to study brain, heart, and liver function in the absence of oxygen, but being anoxia-tolerant likely means that decapitation alone is not a suitable method of euthanasia. Many anesthetics have long-term effects on ion channels and are not appropriate for same day experimentation. Using whole-cell electrophysiological techniques, we examine the effects of the anesthetic, Alfaxalone, on pyramidal cell action potential amplitude, threshold, rise and decay time, width, frequency, whole cell conductance, and evoked GABAA receptors currents to determine if any of these characteristics are altered with the use of Alfaxalone for animal sedation. We find that Alfaxalone has no long-term impact on action potential parameters or whole-cell conductance. When acutely applied to naïve tissue, Alfaxalone did lengthen GABAA receptor current decay rates by 1.5-fold. Following whole-animal sedation with Alfaxalone, evoked whole cell GABAA receptor current decay rates displayed an increasing trend with 1 and 2 hours after brain sheet preparation, but showed no significant change after a 3-hour washout period. Therefore, we conclude that Alfaxalone is a suitable anesthetic for same day use in electrophysiological studies in western painted turtle brain tissue.
An agent for use in targeting tumour cells comprises a compound (6) of a mean molecular weight of no more than about 70,000, and preferably of considerably lower molecular weight; it is thus able to pass relatively readily from the bloodstream into the extra-cellular fluid. The compound is able to become reversibly bound to characteristic antigens (5) on tumour cells (4) and to this end may include fragments (7) of antibodies. The compound also includes a ligand (9) that can become reversibly bound to a binding protein (10) naturally occurring in the bloodstream or introduced into the bloodstream. The complex formed by the compound and binding protein is eliminated from the body only relatively slowly and thus provides a continuing source of the compound for attachment to the tumour antigens. The compound may be radioactive or include a chemotherapeutic constituent. When it is desired to flush the compound from the body, an unreactive substance that competes with the binding protein is introduced into the bloodstream at relatively high concentrations, thus displacing the compound from the binding protein and enabling it to be eliminated by the kidneys.
The present invention relates to a composition containing a herbal medicine extract mixture as an active ingredient for the prevention, alleviation, or treatment of arthritis, and more specifically, to a composition containing a herbal medicine extract mixture as an active ingredient for the prevention, alleviation, or treatment of arthritis, which can be used as heath functional food or a pharmaceutical composition. According to the present invention, the herbal medicine extract mixture (YNH431) inhibits the expression of ERK, p38 MAPK, and NF-kB caused by the excessive proliferation of synovial fibroblasts, thereby having an inflammation inhibitory effect and an excellent inhibitory effect against the differentiation of osteoclasts associated with a fracture in a joint. It is verified that the expression rate of MMPs, COX-2, and PGE2 increased by inflammation is further reduced in the case of using the herbal medicine extract mixture of the present invention than in the case of separately using each herbal medicine extract. Furthermore, the expression of IL-1β and TNF-α, which are inflammatory cytokines, is inhibited in animal models of inflammatory arthritis, thereby inhibiting the generation of arthritis. Also, an effect of inhibiting a fracture in a joint is shown even in histological and micro-CT findings. Therefore, the herbal medicine extract mixture according to the present invention can be practically used for the composition for the prevention, alleviation, or treatment of arthritis. The composition contains, as an active ingredient, a mixture consisting of 30-50 wt% of a Cudrania tricuspidata stem extract, 20-40 wt% of an Angelica gigas Nakai root extract, 5-15 wt% of a Kalopanax Pictus Nakai stem extract, 5-15 wt% of a Sambucus williamsii HANCE var. coreana Nakai stem extract, 1-10 wt% of a Gastrodia elata Blume root extract, and 1-10 wt% of a Clematis chinensis Osbeck root extract.